Nifuratel

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Nifuratel is a nitrofuran derivative indicated in the treatment of leucorrhea, vulvovaginal infections, and urinary tract infections.

Generic Name
Nifuratel
DrugBank Accession Number
DB13724
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 285.27
Monoisotopic: 285.04194164
Chemical Formula
C10H11N3O5S
Synonyms
  • Nifuratel

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to treatBacterial vaginitisCombination Product in combination with: Nystatin (DB00646)••••••••••••
Treatment ofFungal vaginal infections••••••••••••
Treatment ofTrichomonal vaginitis••••••••••••
Used in combination to treatTrichomonal vaginitisCombination Product in combination with: Nystatin (DB00646)••••••••••••
Used in combination to treatVaginal candidiasisCombination Product in combination with: Nystatin (DB00646)••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be increased when used in combination with Nifuratel.
DicoumarolThe therapeutic efficacy of Dicoumarol can be increased when used in combination with Nifuratel.
FluindioneThe therapeutic efficacy of Fluindione can be increased when used in combination with Nifuratel.
PhenindioneThe therapeutic efficacy of Phenindione can be increased when used in combination with Nifuratel.
PhenprocoumonThe therapeutic efficacy of Phenprocoumon can be increased when used in combination with Nifuratel.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
INIMUR COMPLEXNifuratel (10 g/100g) + Nystatin (4000000 IU)CreamVaginalPolichem S.R.L.2014-07-08Not applicableItaly flag
INIMUR COMPLEXNifuratel (500 MG) + Nystatin (200000 IU)CapsuleVaginalPolichem S.R.L.2014-07-08Not applicableItaly flag
INIMUR COMPLEXNifuratel (500 MG) + Nystatin (200000 IU)CapsuleVaginalPolichem S.R.L.2014-07-08Not applicableItaly flag
MACMIROR COMPLEXNifuratel (500 MG) + Nystatin (200000 IU)InsertVaginalGmm Farma S.R.L.2020-02-152022-10-29Italy flag
MACMIROR® COMPLEXNifuratel (500 mg) + Nystatin (200000 IU)CapsuleVaginalDOPPEL FARMACEUTICI S.R.L.2010-02-01Not applicableColombia flag

Categories

ATC Codes
G01AX05 — Nifuratel
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as nitrofurans. These are compounds containing a furan ring which bears a nitro group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Furans
Sub Class
Nitrofurans
Direct Parent
Nitrofurans
Alternative Parents
Nitroaromatic compounds / Oxazolidinones / Heteroaromatic compounds / Organic carbonic acids and derivatives / Sulfenyl compounds / Propargyl-type 1,3-dipolar organic compounds / Oxacyclic compounds / Organic oxoazanium compounds / Dialkylthioethers / Azacyclic compounds
show 5 more
Substituents
2-nitrofuran / Allyl-type 1,3-dipolar organic compound / Aromatic heteromonocyclic compound / Azacycle / C-nitro compound / Carbonic acid derivative / Carbonyl group / Dialkylthioether / Heteroaromatic compound / Hydrocarbon derivative
show 17 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
U60U6P08SP
CAS number
4936-47-4
InChI Key
SRQKTCXJCCHINN-NYYWCZLTSA-N
InChI
InChI=1S/C10H11N3O5S/c1-19-6-8-5-12(10(14)18-8)11-4-7-2-3-9(17-7)13(15)16/h2-4,8H,5-6H2,1H3/b11-4+
IUPAC Name
5-[(methylsulfanyl)methyl]-3-[(E)-[(5-nitrofuran-2-yl)methylidene]amino]-1,3-oxazolidin-2-one
SMILES
CSCC1CN(\N=C\C2=CC=C(O2)[N+]([O-])=O)C(=O)O1

References

General References
  1. AIFA Product Information: Nifuratel Farmitalia for oral or vaginal use [Link]
  2. TITCK Product Information: Nifunis (nifuratel/nystatin) vaginal suppository [Link]
ChemSpider
4938579
RxNav
7419
ChEBI
135180
ChEMBL
CHEMBL514315
Wikipedia
Nifuratel

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletVaginal
CreamVaginal
InsertVaginal
InsertVaginal500 mg
SuppositoryVaginal
CreamVaginal10 %
TabletVaginal250 MG
Tablet, coatedOral200 MG
CapsuleVaginal
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.109 mg/mLALOGPS
logP0.95ALOGPS
logP1.72Chemaxon
logS-3.4ALOGPS
pKa (Strongest Basic)-2.1Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area98.18 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity66.88 m3·mol-1Chemaxon
Polarizability27.28 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-01p2-9230000000-6b014b7e904925e8ceda
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-159.28606
predicted
DeepCCS 1.0 (2019)
[M+H]+162.54613
predicted
DeepCCS 1.0 (2019)
[M+Na]+170.60045
predicted
DeepCCS 1.0 (2019)

Drug created at June 23, 2017 20:47 / Updated at May 22, 2021 06:01